Fig 1: IMD for separating cancer cells and SCTA-chip for identifying cancer cells. (a) Recovery rates of seven cancer cell lines at different numbers of cells (n = 9 for each cell line). (b) Capture rate of AGS cells at different numbers. (c) Finite element analysis using COMSOL Multiphysics for the SCTA chip: flow velocity distribution on the chip. (d) Finite element analysis using COMSOL Multiphysics for the SCTA chip: flow velocity streamlines on the chip. (e) Confocal fluorescence images of CD45/EpCAM/YAP1/HER-2 and Wright-Giemsa staining of AGS cells on the SCTA-chip. Scale bar, 8 µm (The minimum gap of a single cell trap, 8 µm).
Fig 2: Serial analysis of HER-2 expression in tissues and ascites cancer cells. (a) HER-2 expression and Wright-Giemsa staining in NATs, primary cancer lesions, lymph node metastasis/TD, and ascites cancer cells for P04–P07. *TD for P04 and P07; Lymph node metastasis for P05 and P06. (b) HER-2 expression and Wright-Giemsa staining in primary cancer lesions and ascites cancer cells for P08 and P09. (c) HER-2 and Wright-Giemsa staining in ascites cancer cells for P01, P02, P03, P10, P11, and P12. Expression in tissues (NATs, primary cancer lesions, and lymph node metastasis/TD) analyzed by IHC, scale bar, 300 µm; Expression in ascites cancer cells analyzed by in situ immunofluorescence, Scale bar, 8 µm (The minimum gap of a single cell trap, 8 µm).
Supplier Page from Abcam for Anti-ErbB2 / HER2 antibody [EPR19547-12] (Alexa Fluor® 488)